Prothena Corporation (PRTA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.31
- Estimate
- -$0.38
- Surprise
- +18.4%
- Revenue (period 2026-06-30)
- $1.0M
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
Prothena Corporation (PRTA) reported a narrower loss than forecast — adjusted EPS of -$0.31 against the -$0.38 estimate (a 18.4% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates PRTA Sell at 5.0/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +18.4% surprise compares with a +79.6% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (1.8 < 4.0)
- Value-trap signals (2/5): Material insider selling (24 sells, 0.19% of cap), Negative free cash flow
- Momentum score 2.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.02
- Price target
- $18.62
- Stop
- $7.57
- Upside to target
- +132.2%
- Reward-to-risk
- 12.8:1
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
PRTA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $411.7M
- P/E (fwd)
- -5.3
- 52-week range
- $7.73–$11.80
- Off 52-week high
- 32.0%
- RSI (14)
- 47
- Volume vs avg
- 0.98×
- Score today
- 5.0/10